---
title: "The Brain After Death: How BrainEx Technology is Changing the Rules of Pharmaceuticals and Saving Lives"
description: "American startup Bexorg has introduced a technology that maintains the viability of the human brain after death. This allows for drug testing on real human cells, bypassing inaccurate mouse experiments. 🧠💉"
date: 2026-05-27T12:45:00.000Z
lang: en
url: https://xab.info/en/posts/the-brain-after-death-how-brainex-technology-is-changing-the-rules-of-pharmaceuticals-and-saving-lives
tags: []
publisher: "XAB.info"
---

# The Brain After Death: How BrainEx Technology is Changing the Rules of Pharmaceuticals and Saving Lives

![Schematic image of a neural network with active glowing nodes, symbolizing the work of BrainEx technology](https://xab.info/media/2026/05/27/mozg-posle-smerti-tekhnologiya-brainex-menyayet-farmacevtiku/neironnaya-set-mozg-tekhnologiya-brainex.webp)

The boundary between life and death, which we once considered unshakable, is beginning to blur. American startup Bexorg has introduced the world to the BrainEx platform, capable of maintaining biological activity in a human brain several hours after the clinical death of its owner. This is not an attempt to revive a person, but a revolutionary tool for combating incurable diseases.

### A Living Laboratory in a Test Tube

The idea behind BrainEx was born ten years ago at Yale University. The essence of the method is simple yet shocking: surgeons connect a donor brain to an artificial circulation system. Special ports replace natural vessels, pumping liters of nutrient solution through the organ. Built-in artificial lungs and kidneys saturate the tissues with oxygen and remove toxins.

In this state, the brain continues to live and function. It metabolizes experimental drugs, responds to stimuli, and allows scientists to observe processes in real-time. Sensors record hundreds of metrics, and after 24 hours, the organ is dissected into hundreds of samples for deep analysis of cell and protein structure.

### Why Is This Better Than Mice?

Traditional pharmacology has relied on testing on rodents for decades. But a mouse brain is not a human brain. Here lies the main advantage of BrainEx: donor organs carry unique genetics, a history of diseases, and the imprint of 60–80 years of life in a real environment.

Already, the results of the platform's work are impressive. Pharmaceutical company Biohaven tested a Parkinson's disease drug on brains from Bexorg. The drug showed no efficacy on mice, but worked perfectly on the human organ, at a dosage 20 times lower than calculated. This discovery saved the company a whole year of development and allowed the FDA to launch clinical trials for the new compound BHV-8100.

### Ethics and the Future

Experiments in 2019 on pig brains sparked a storm of ethical debate: would they feel pain? Would consciousness return? Bexorg's answer is unequivocal: the technology suppresses the electrical activity necessary for consciousness but preserves cellular viability. Since diseases like Alzheimer's or ALS are not electrical failures but biochemical processes, suppressing impulses does not hinder research.

Currently, the company is scaling production. A new laboratory will feature a robotic arm capable of processing up to 1,600 brains per year. Plans include extending the life-support period to two weeks to study long-term processes, as well as creating an AI model called NeuroLens. This "virtual brain" will be trained on real data, allowing drug molecules to be tested in simulation before working with physical organs.